No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Zhejiang Huahai Pharmaceutical Co., Ltd. is a China-based pharmaceutical enterprise with a global presence. Its diverse portfolio encompasses treatments for central nervous system disorders, cardiovascular conditions, and viral infections, among other finished pharmaceutical products. Beyond finished drugs, the company also produces Active Pharmaceutical Ingredients (APIs) and crucial intermediates. Huahai Pharmaceutical further engages in the manufacturing of packaging components, notably high-density polyethylene (HDPE) bottles and polypropylene (PP) caps. Additionally, it offers contract manufacturing (CMO) and other specialized services, while also playing a role in import and export trade services. Established in 1989, the company maintains its headquarters in Linhai, China.
www.huahaipharm.comNo one on the platform currently holds 600521.SS.
No tracked institution reports a position in 600521.SS as of their last filing.
No one on the platform has traded 600521.SS yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 1.9% | 6.2% | 7.8% | — | — | — |
| Rev. Growth % | -10.6% | 5.7% | ||||
| Profit Margin % | 3.1% | 9.3% | 9.8% | |||
| Free Cash Flow Margin % | -8.6% | -6.7% | -4.4% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $9.3B | +9.5% | $0.68 | $0.52–$0.84 | — | 2 |
| 2027 | $10.1B | +8.9% | $0.63 | $0.62–$0.65 | — | 1 |
| 2028 | $11.3B | +12.1% | $0.95 | $0.93–$0.98 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 3 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-26 | $0.24 | $0.24 | +0.0% |
| 2026-04-30 | $0.17 | $0.27 | +54.3% |
| 2026-04-15 | $-0.06 | $-0.08 | -33.3% |
| 2025-10-29 | $0.15 | $-0.02 | -112.9% |
| 2025-08-25 | $0.08 | $0.07 | -12.5% |
| 2025-04-29 | $0.17 | $0.11 | -37.1% |
| 2025-04-29 | $0.17 | $0.06 | -65.7% |
| 2024-10-30 | $0.18 | $0.19 | +5.6% |
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| 600521.SSZhejiang Huahai Pharmaceutical Co., Ltd. | $16.20 | +4.38% | $24.3B | — |
| 000423.SZDong-E-E-Jiao Co.,Ltd. | $45.98 | -0.28% | $29.4B | — |
| 000513.SZLivzon Pharmaceutical Group Inc. | $26.21 | -1.39% | $23.3B | — |
| 000623.SZJilin Aodong Pharmaceutical Group Co., Ltd. | $17.44 | +0.23% | $20.9B | — |
| 000766.SZTonghua Golden-Horse Pharmaceutical Industry Co,Ltd |
| $15.29 |
| -2.36% |
| $14.8B |
| — |
| 002262.SZJiangsu Nhwa Pharmaceutical Co., Ltd. | $21.59 | -0.28% | $21.9B | — |
| 002773.SZChengdu Kanghong Pharmaceutical Group Co., Ltd | $19.11 | -0.10% | $17.6B | — |
Source: Financial Modeling Prep · peers by sector/industry